Combination of fosinopril and pravastatin decreases platelet response to thrombin receptor agonist in monkeys

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 18, Issue 10, 1998, Pages 1643-1646

  Paulette Hale, L ^a   Craver, Karen T ^a   Berrier, Alan M ^a   Sheffield, Matthew V ^b   Douglas Case, L ^a   Owen, John ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b Clinical Pathology Consultants   (United States)

Author keywords

3 hydroxy 3 methylglutaryl coenzyme A reductase inhibitors; Angiotensin converting enzyme inhibitors; Platelet aggregation

Indexed keywords

COLLAGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOSINOPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN;

ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; MONKEY; NONHUMAN; OUTCOMES RESEARCH; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOSIS;

EID: 17344372699     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.atv.18.10.1643     Document Type: Article

References (14)

1. Rack JM, Yunis C. Therapeutic implications of the epidemiology and timing of myocardial infarction and other cardiovascular diseases. J Hum Hypertens. 1997;11:23-28.
2. Shah PK. Pathophysiology of plaque rupture and the concept of plaque stabilization. Cordial Clin. 1996;14:17-29.
3. Pitt B. The potential use of angiotensin-converting enzyme inhibitors in patients with hyperlipidemia. Am J Cardiol. 1997;79:24-28.
4. Pepine CJ. Ongoing clinical trials of angiotensin-converting enzyme inhibitors for treatment of coronary artery disease in patients with preserved left ventricular function. J Am Coll Cordial. 1996;27: 1048-1052.
5. Born GVR, Cross MJ. The aggregation of blood platelets. J Physiol. 1963;168:178-195.
6. Someya N, Morotomi Y, Kodama K, Kida O, Higa T, Kondo K, Tanaka K. Suppressive effect of captopril on platelet aggregation in essential hypertension. J Cardiovasc Phannacol. 1984;6:840-843.
7. Gupta RK, Kjeldsen SE, Motley E, Weder AB, Zweifler AJ, Julius S. Platelet function during antihypertensive treatment with quinapril, a novel angiotensin converting enzyme inhibitor. J Cardiovasc Pharmacol. 1991; 17:13-19.
8. Zannad F, Bray-Desboscs L, el Ghawi R, Donner M, Thibout E, Stoltz, JF. Effects of lisinopril and hydrochlorothiazide on platelet function and blood rheology in essential hypertension: a randomly allocated double-blind study. J Hypertens. 1993;11:559-564.
9. Keidar S, Oiknine J, Leiba A, Shapira C, Leiba M, Aviram M. Fosinopril reduces ADP-induced platelet aggregation in hypertensive patients. J Cardiovasc Pharmacol. 1996;27:183-186.
10. Brook G, Winterstein G, Aviram M. Platelet function and lipoprotein levels after plasma-exchange in patients with familial hypercholesterolaemia. Clin Sci. 1983;64:637-642.
11. Hassall DG, Forrest LA, Bruckdorfer KR, Marenah CB, Turner P, Cortese C, Miller NE, Lewis B. Influence of plasma lipoproteins on platelet aggregation in a normal male population. Arteriosclerosis. 1983; 3:332-338.
12. Beigel Y, Fuchs J, Snir M, Green P, Lurie Y, Djaldetti M. Lovastatin therapy in hypercholesterolemia: effect on fibrinogen, hemorrheologic parameters, platelet activity, and red blood cell morphology. J Clin Pharmacol. 1991;31:512-517.
13. Broijersén A, Eriksson M, Larsson PT, Beck O, Berglund L, Angelin B, Hjemdahl P. Effects of selective LDL-apheresis and pravastatin therapy on platelet function in familial hypercholesterolaemia. Eur J Clin Invest. 1994;24:488-496.
14. Mayer J, Eller T, Brauer P, Solleder EM, Schäfer RM, Keller F, Kochsiek K. Effects of long-term treatment with lovastatin on the clotting system and blood platelets. Ann Hematol. 1992;64:196-201.